BioPharmSignal logoBioPharmSignal

Biotech News

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Pulmatrix (PULM)PulmatrixCompany update

PULM (PULM) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is pulm.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

PULMPulmatrix2026-03-26 12:00 EST

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

PULMPulmatrix2026-03-02 13:00 EST

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

View all latest news

Pulmatrix

Pulmatrix is a biotechnology company focused on inhaled therapies and pulmonary disease. Its platform seeks to deliver drugs directly to the lungs to improve local exposure and tolerability.

Recent company news

PULMPulmatrix2026-05-15 12:20 EST

Pulmatrix Announces First Quarter 2026 Financial Results

PULMPulmatrix2026-04-21 12:00 EST

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

PULMPulmatrix2026-03-26 12:00 EST

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

PULMPulmatrix2026-03-02 13:00 EST

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

PULMPulmatrix2026-02-26 13:05 EST

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Stock data

Close
1.66 USD
Market cap
4.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States